Intérêt de l’élastométrie (FibroScan®) pour l’évaluation non invasive de la fibrose hépatique

Castéra, Laurent

doi:10.1016/s0399-8320(07)89422-x

Cited by 15 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FibroScan ® was developed by Echosens (Paris, France) in 2003 13 . The equipment consists of a 5-MHz US transducer coupled to a base with a vibratory axis, and it uses VCTE technology (elastography technology with velocity-controlled impulses).…”

Section: Methodsmentioning

confidence: 99%

“…The results of liver elasticity measurements are expressed in kilopascals (kPa) in an interval of 2.5-75 kPa. The section analyzed corresponds to a cylinder 1 cm in diameter and 4 cm in length, corresponding to a volume 100-fold larger than that obtained with liver biopsy 11 , 13 - 15 . A liver stiffness assessment is generally considered reliable when the following criteria are fulfilled: 10 valid measurements, success rate >60%, and ratio of the interquartile range to the median (IQR/M) ≤30% 16 - 18 .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C

Ragazzo¹,

Paranaguá‐Vezozzo²,

Lima³

et al. 2017

Clinics

View full text Add to dashboard Cite

OBJECTIVES:Although liver biopsy is the gold standard for determining the degree of liver fibrosis, issues regarding its invasiveness and the small amount of liver tissue evaluated can limit its applicability and interpretation in clinical practice. Non-invasive evaluation methods for liver fibrosis can address some of these limitations. The aim of this study was to evaluate the accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI), enhanced liver fibrosis (ELF), the aspartate aminotransferase-to-platelet ratio index (APRI), and the FIB-4 index compared with liver biopsy in hepatitis C.METHODS:We evaluated chronic hepatitis C patients who were followed at the Division of Clinical Gastroenterology and Hepatology, Hospital das Clínicas, Department of Gastroenterology of University of São Paulo School of Medicine, São Paulo, Brazil, and who underwent liver biopsy. The accuracy of each method was determined by a receiver operating characteristic (ROC) curve analysis, and fibrosis was classified as significant fibrosis (≥F2), advanced fibrosis (≥F3), or cirrhosis (F4). The Obuchowski method was also used to determine the diagnostic accuracy of each method at the various stages of fibrosis. In total, 107 FibroScan®, 51 ARFI, 68 ELF, 106 APRI, and 106 FIB-4 analyses were performed.RESULTS:A total of 107 patients were included in the study. The areas under the ROC curve (AUROCs) according to fibrosis degree were as follows: significant fibrosis (≥F2): FibroScan®: 0.83, FIB-4: 0.76, ELF: 0.70, APRI: 0.69, and ARFI: 0.67; advanced fibrosis (≥F3): FibroScan®: 0.85, ELF: 0.82, FIB-4: 0.77, ARFI: 0.74, and APRI: 0.71; and cirrhosis (F4): APRI: 1, FIB-4: 1, FibroScan®: 0.99, ARFI: 0.96, and ELF: 0.94. The accuracies of transient elastography, ARFI, ELF, APRI and FIB-4 determined by the Obuchowski method were F0-F1: 0.81, 0.78, 0.44, 0.72 and 0.67, respectively; F1-F2: 0.73, 0.53, 0.62, 0.60, and 0.68, respectively; F2-F3: 0.70, 0.64, 0.77, 0.60, and 0.67, respectively; and F3-F4: 0.98, 0.96, 0.82, 1, and 1, respectively.CONCLUSION:Transient elastography remained the most effective method for evaluating all degrees of fibrosis. The accuracy of all methodologies was best at F4.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C

Ragazzo¹,

Paranaguá‐Vezozzo²,

Lima³

et al. 2017

Clinics

View full text Add to dashboard Cite

show abstract

“…A limitation of our results could be the relatively small number of specimens (20). So it is recommended that further work should be carried out to confirm the results obtained here taking a relatively large number and at the same time introducing the stage F2 that is not in this study.…”

Section: Discussionmentioning

confidence: 77%

“…Figure 5 illustrates a clear separation between the different regions occupied each group. This is a promising indication that the multipatametric ultrasonic parameter may be useful for the prediction of liver fibrosis, especially for stages +RZHYHU WKH HODVWRJUDSKLF PHWKRGV VHHP WR EH more appropriate for the fibrosis [18][19][20]. So, this multiparametric study could play could be seen as complementary to the elastographic methods in order to predict all fibrosis stages.…”

Section: Discussionmentioning

confidence: 94%

Hepatitis fibrosis characterization by a multiparametric study

Meziri

Bouzitoune

Remita

et al. 2013

The Journal of the Acoustical Society of America

View full text Add to dashboard Cite

The Ultrasonic Tissue Characterization (UTC) is primarily based on radio-frequency (RF) signals′analysis. The processing of these signals allowed the estimation of different quantitative ultrasonic parameters (backscattered coefficients-ICB-, velocity-SoS, etc). It is known that the RF contains information that can be used to noninvasively characterize the structural and mechanical properties of tissue. Scatterer diameter (or size) from ICB measurements have been already used to discriminate fibrosis from normal tissue. From these findings, our goal was to evaluate the scatterer diameter to test its potential in the discrimination of fibrosis groups (F0, F1, F2, F3, and F4, METAVIR scale) from 20 in-vitro human liver samples, explored at 20 MHz. The mean scatterer diameters (µm) measured were: 42.14±4.90 (F0), 40.18±10.51 (F1), 38.82±6.05 (F3) and 40.30±2.22 (F4). The Kolmogorov-Smirnov test has shown a non-significant level (p>0.05) indicating that the scatterer size estimation alone cannot differentiate between all fibrosis groups; an obvious overlap between groups appears. However, fr the two different combinations (ICB, Size) and (ICB, Size, SoS), the discriminant analysis has correctly classified 75% and 85%, respectively, of liver samples at a significant level (p<0.00005). The multiparametric study could play an important role to aid in the diagnostic of liver fibrosis.

show abstract

“…It is critical for fibrosis patients to obtain an accurate diagnosis in the early stages to receive adequate therapy. However, an overlap between early stages of fibrosis (control/F0, F1, and sometimes F2) has been discovered by both elastographic methods and ultrasonic approaches [ 10 , 11 , 16 – 18 ]. It is difficult to differentiate between the F0 and F1 (and sometimes F2) stages, but the identification of changes between early stages is essential for doctors to determine proper treatment schemes for fibrosis patients.…”

Section: Introductionmentioning

confidence: 99%

Proteomic Analysis of Human Serum for Patients at Different Pathological Stages of Hepatic Fibrosis

Zhao

Huang

Xia

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background. Hepatic fibrosis is a severe liver disease that has threatened human health for a long time. In order to undergo timely and adequate therapy, it is important for patients to obtain an accurate diagnosis of fibrosis. Laboratory inspection methods have been efficient in distinguishing between advanced hepatic fibrosis stages (F3, F4), but the identification of early stages of fibrosis has not been achieved. The development of proteomics may provide us with a new direction to identify the stages of fibrosis. Methods. We established serum proteomic maps for patients with hepatic fibrosis at different stages and identified differential expression of proteins between fibrosis stages through ultra-high-performance liquid chromatography tandem mass spectrometry proteomic analysis. Results. From the proteomic profiles of the serum of patients with different stages of liver fibrosis, a total of 1,338 proteins were identified. Among three early fibrosis stages (control, F1, and F2), 55 differential proteins were identified, but no proteins simultaneously exhibited differential expression between control, F1, and F2. Differential proteins were detected in the comparison between different fibrosis stages. Significant differences were found between advanced fibrosis stages (F2-vs.-F3 and F3-vs.-F4) through a series of statistical analysis, including hierarchical clustering, Gene Ontology (GO) functional annotation, Kyoto Encyclopedia of Genes and Genomes pathway, and protein-protein interaction network analysis. The differential proteins identified by GO annotation were associated with biological processes (mainly platelet degranulation and cell adhesion), molecular functions, and cellular components. Conclusions. All potential biomarkers identified between the stages of fibrosis could be key points in determining the fibrosis staging. The differences between early stages may provide a useful reference in addressing the challenge of early fibrosis staging.

show abstract

Intérêt de l’élastométrie (FibroScan®) pour l’évaluation non invasive de la fibrose hépatique

Cited by 15 publications

References 27 publications

Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C

Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C

Hepatitis fibrosis characterization by a multiparametric study

Proteomic Analysis of Human Serum for Patients at Different Pathological Stages of Hepatic Fibrosis

Contact Info

Product

Resources

About